Cihan Yasemin Benderli, Ozturk Ahmet, Arslan Alaettin, Deniz Kemal, Baran Munevver, Karaca Halit
Department of Radiation Oncology, Kayseri Education and Research Hospital, Kayseri, Turkey E-mail :
Asian Pac J Cancer Prev. 2014;15(10):4117-23. doi: 10.7314/apjcp.2014.15.10.4117.
To determine prognostic value of excision repair cross-complementation 1 (ERCC1) in patients with malignant pleural mesothelioma (MPM).
The study included 60 patients with MPM who were diagnosed and treated in the Radiation Oncology Department of Kayseri Teaching Hospital and Medical Oncology Department of Erciyes University, Medicine School between 2005 and 2013. By using immunohistochemical methods, ERCC1 expression in biopsy specimens was evaluated. We retrospectively assessed whether there is a correlation between ERCC1 and response to anti-neoplastic therapy or survival.
There were 50 men and 10 women with median age of 62 years (range: 39-83). Histological type was epithelial mesothelioma in the majority of the cases (85%), most commonly presenting in stage four. Of the cases, 20 (33%) received radiotherapy, 60 (%100) received first-line chemotherapy and 15 (%25) received second-line chemotherapy. In the assessment after therapy, it was found that there was partial response in 12 cases (20%), stable disease in 19 cases (31.4%) and progression in 25 cases (41.7%). ERCC1 was positive in 43% of the cases. Mean OS was 11.7 months and mean DFS was 9.5 months in ERCC1-positive cases regardless of therapy, while they were 19.2 months and 17.1 months in ERCC1-negative cases, respectively. The difference was found to be significant (p<0.05). In univariate analysis, stage, comorbidity, response to treatment and ERCC1 expression were found to be significantly associated with OS (p=0.083; p=0.043; p=0.041; p=0.050). In multivariate analysis, response to treatment remained to be significant for OS (p=0.005). In univariate and multivariate analyses, response to treatment and ERCC1 were found to be significantly associated with DFS (p=0.049; p=0.041).
ERCC1 was identified as poor prognostic factor in patients with MPM.
确定切除修复交叉互补基因1（ERCC1）在恶性胸膜间皮瘤（MPM）患者中的预后价值。
本研究纳入了2005年至2013年间在开塞利教学医院放射肿瘤科和埃尔西耶斯大学医学院医学肿瘤科诊断并接受治疗的60例MPM患者。采用免疫组化方法评估活检标本中ERCC1的表达。我们回顾性评估了ERCC1与抗肿瘤治疗反应或生存之间是否存在相关性。
患者中有50名男性和10名女性，中位年龄为62岁（范围：39 - 83岁）。大多数病例（85%）的组织学类型为上皮性间皮瘤，最常见于IV期。其中，20例（33%）接受了放疗，60例（100%）接受了一线化疗，15例（25%）接受了二线化疗。治疗后评估发现，12例（20%）部分缓解，19例（31.4%）病情稳定，25例（41.7%）病情进展。43%的病例ERCC1呈阳性。无论治疗情况如何，ERCC1阳性病例的平均总生存期（OS）为11.7个月，平均无病生存期（DFS）为9.5个月，而ERCC1阴性病例的平均OS和DFS分别为19.2个月和17.1个月。差异具有统计学意义（p<0.05）。单因素分析中，分期、合并症、治疗反应和ERCC1表达均与OS显著相关（p = 0.083；p = 0.043；p = 0.041；p = 0.050）。多因素分析中，治疗反应对OS仍具有显著意义（p = 0.005）。单因素和多因素分析中，治疗反应和ERCC1均与DFS显著相关（p = 0.049；p = 0.041）。
ERCC1被确定为MPM患者的不良预后因素。
